Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
8.85
+0.09 (1.03%)
At close: Aug 7, 2026, 4:00 PM EDT
8.65
-0.20 (-2.26%)
Pre-market: Aug 10, 2026, 7:20 AM EDT

Cartesian Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.482.838.9126110.7885.08
Revenue Growth
43.96%-92.81%49.64%-76.53%30.21%412.61%
Gross Profit
1.482.838.9126110.7885.08
Operating Income
-155.36-143.41-43.9-86.4214.54-4.6
Net Income
13.72-130.3-77.42-219.7135.38-25.69
Earnings Per Share
-5.95-5.02-4.49-49.760.10-0.22
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
147.61125.14212.6176.91134.6128.06
Total Debt
63.8512.6813.9810.9637.9334.23
Net Cash (Debt)
83.75112.46198.6365.9696.6893.82
Net Cash Growth
-44.45%-43.38%201.15%-31.78%3.04%-10.00%
Net Cash Per Share
3.084.3311.440.450.660.82

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-76.53-73.94-23.67-51.16-31.63-60.38
Capital Expenditures
-2.08-5.45-9.09-0.21-1.2-1.09
Free Cash Flow
-78.61-79.4-32.77-51.37-32.83-61.47
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-10518.60%-5127.10%-112.81%-332.32%13.12%-5.40%
Pretax Margin
-10848.68%-4987.31%-198.23%-917.97%31.39%-11.43%
Profit Margin
-10283.80%-4658.63%-198.97%-844.91%31.94%-30.19%
FCF Margin
-5322.41%-2838.58%-84.21%-197.53%-29.64%-72.25%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----339.00-
PS Ratio
181.2967.0511.864.291.564.74